ReviewFrontiers in microbiology2015
Bacterial Vaginosis Biofilms: Challenges to Current Therapies and Emerging Solutions.
Review in Frontiers in microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 1 synthesis or guideline pooled it, 207 citations in OpenAlex.
- Contribution ofFrontiers in cellular and infection microbiology · 2021Pooled it
- Human Trial for the Effect of Plasma-Activated Water Spray on Vaginal Cleaning in Patients with Bacterial Vaginosis.Medical sciences (Basel, Switzerland) · 2022Trial
- Trial
- Trial
- Trial
- Treatment of biofilms in bacterial vaginosis by an amphoteric tenside pessary-clinical study and microbiota analysis.Microbiome · 2017Trial
- The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment.Microbiome · 2017Trial
- Enhanced activity of octiset® versus octenidine against polymicrobial bacterial vaginosis biofilmsBiofilm · 2026Article
- Microbiota and inflammatory factor profiles in different stages of bacterial vaginosis formation and recurrence.Journal of medical microbiology · 2026Article
- The Gut-Vagina Axis.Microorganisms · 2026Review
- Prospective study of vaginal samples for the detection ofMicrobiology spectrum · 2026Article
- Selective Human-Milk-Inspired Antimicrobial Peptides for the Treatment of Bacterial Vaginosis.Pharmaceutics · 2026Article
- Regulatory Effects ofMicroorganisms · 2026Article
- Article
- Multi-kingdom cervical microbiome structure in health and dysbiosis: a cross-sectional study from Kazakhstan.Frontiers in microbiology · 2026Article
- β-Cyclodextrin Inclusion Complexes of Curcumin and Synthetic Analogues in PVA/Carrageenan Hydrogels: A Platform for Sustained Release and Microbial Control.Gels (Basel, Switzerland) · 2025Article
- Hallmarks of Bacterial Vaginosis.Diagnostics (Basel, Switzerland) · 2025Review
- The Prevalence of Bacterial Vaginosis in Pregnant Women in Slovenia, Determined via Microscopy and Semi-Quantitative Relative Culture, and Its Association with Adverse Pregnancy Outcomes.Microorganisms · 2025Article
- In Vitro Bactericidal Activity of a Neomycin-Polymyxin B-Nystatin Combination Compared to Metronidazole and Clindamycin Against the Main Bacteria Involved in Bacterial Vaginosis and Aerobic Vaginitis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Syntrophic bacterial and host-microbe interactions in bacterial vaginosis.The ISME journal · 2025Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial vaginosis (BV) is the most common genital tract infection in women during their reproductive years and it has been associated with serious health complications, such as preterm delivery and acquisition or transmission of several sexually transmitted agents. BV is characterized by a reduction of beneficial lactobacilli and a significant increase in number of anaerobic bacteria, including Gardnerella vaginalis, Atopobium vaginae, Mobiluncus spp., Bacteroides spp. and Prevotella spp.. Being polymicrobial in nature, BV etiology remains unclear. However, it is certain that BV involves the presence of a thick vaginal multi-species biofilm, where G. vaginalis is the predominant species. Similar to what happens in many other biofilm-related infections, standard antibiotics, like metronidazole, are unable to fully eradicate the vaginal biofilm, which can explain the high recurrence rates of BV. Furthermore, antibiotic therapy can also cause a negative impact on the healthy vaginal microflora. These issues sparked the interest in developing alternative therapeutic strategies. This review provides a quick synopsis of the currently approved and available antibiotics for BV treatment while presenting an overview of novel strategies that are being explored for the treatment of this disorder, with special focus on natural compounds that are able to overcome biofilm-associated antibiotic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.